Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKesson
Baxter

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CASPOFUNGIN ACETATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Caspofungin Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00008359 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed National Cancer Institute (NCI) Phase 3 2000-08-01 RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy.
NCT00008359 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed Memorial Sloan Kettering Cancer Center Phase 3 2000-08-01 RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy.
NCT00020527 Caspofungin Acetate in Treating Children With Fever and Neutropenia Completed National Cancer Institute (NCI) N/A 2001-03-01 RATIONALE: Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation. PURPOSE: Clinical trial to study the effectiveness of caspofungin acetate in treating children who have fever and neutropenia caused by a weakened immune system.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Caspofungin Acetate

Condition Name

Condition Name for Caspofungin Acetate
Intervention Trials
Fungal Infection 6
Candidiasis 4
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Caspofungin Acetate
Intervention Trials
Mycoses 8
Candidiasis 5
Neutropenia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Caspofungin Acetate

Trials by Country

Trials by Country for Caspofungin Acetate
Location Trials
United States 74
Canada 7
Spain 5
France 2
Slovakia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Caspofungin Acetate
Location Trials
Tennessee 3
New York 3
Oregon 2
Mississippi 2
Nebraska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Caspofungin Acetate

Clinical Trial Phase

Clinical Trial Phase for Caspofungin Acetate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Caspofungin Acetate
Clinical Trial Phase Trials
Completed 10
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Caspofungin Acetate

Sponsor Name

Sponsor Name for Caspofungin Acetate
Sponsor Trials
Merck Sharp & Dohme Corp. 6
National Cancer Institute (NCI) 5
European Organisation for Research and Treatment of Cancer - EORTC 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Caspofungin Acetate
Sponsor Trials
Other 9
Industry 6
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Johnson and Johnson
Merck
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.